807620-95-7

Basic information

• Product Name: Acetamide, N-(3-bromo-5-fluorophenyl)-
• CAS NO: 807620-95-7
• Molecular Formula: C8H7BrFNO
• Molecular Weight: 232.052
• Mol File: 807620-95-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Acetamide, N-(3-bromo-5-fluorophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetamide, N-(3-bromo-5-fluorophenyl)-(807620-95-7)
• EPA Substance Registry System: Acetamide, N-(3-bromo-5-fluorophenyl)-(807620-95-7)

Safety Data

• Hazardous Substances Data: 807620-95-7(Hazardous Substances Data)

Upstream product

• 60-35-5 acetamide 
• 1435-51-4 1,3-dibromo-5-fluorobenzene 

Downstream Products

• 134168-98-2 3-bromo-5-fluoroaniline hydrochloride 
• 807620-97-9 2-{2-[3-fluoro-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-2H-tetrazol-5-yl}-pyridine 
• 807620-96-8 2-[2-(3-bromo-5-fluoro-phenyl)-2H-tetrazol-5-yl]-pyridine 
• 710348-95-1 3-fluoro-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)aniline 
• 507269-27-4 3-fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 
• 210992-28-2 3-amino-5-fluoro-benzonitrile 
• 134168-97-1 3-bromo-5-fluoroaniline 

Relevant articles and documents

3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: Identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists

Structure-activity relationship studies on the phenyl ring of 3-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 2 led to the discovery that small, non-hydrogen bond donor substituents at the 3-position led to a substantial increase in in vitro potency. In particular, 3-fluoro-5-(5-pyridin- 2-yl-2H-tetrazol-2-yl)benzonitrile (7) is a highly potent and selective mGlu5 receptor antagonist with good rat pharmacokinetics, brain penetration, and in vivo receptor occupancy.

INHIBITORS OF JUN N-TERMINAL KINASE

The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula (I): or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.

3-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4-methylpyridine: A highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonist

Structure-activity relationship studies performed around 3-fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile for the purposes of developing novel mGlu5 receptor antagonists are described. Synthesis of a series of four-ring tetrazoles led to the discovery of 3-[3-fluoro-5-(5-pyridin-2-yl- 2H-tetrazol-2-yl)phenyl]-4-methylpyridine (26), a highly potent, brain penetrant, tetrazole-based mGlu5 receptor antagonist. Structure-activity relationship studies performed around 3-fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2- yl)benzonitrile for the purpose of developing novel mGlu5 receptor antagonists are described. Synthesis of a series of four-ring tetrazoles led to the discovery of 3-[3-fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4- methylpyridine, a highly potent, brain penetrant, azole-based mGlu5 receptor antagonist.